Semaglutide and the GLP-1 Drug Class Explained

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub, this article explains the GLP-1 hormone, its drug class, and the genetics beneath the pathway.

The phrase "semaglutide GLP-1" is really a question about a drug class, not a single product. To answer it well, this page starts with the hormone itself, moves to how receptor agonists borrow its biology, lists the medications that belong to the class, and lays out their shared safety story before turning to the genes underneath it all.

GLP-1 the hormone

Glucagon-like peptide-1 is an incretin hormone released by enteroendocrine L-cells in the small intestine in response to food. It prompts glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon from alpha cells, slows gastric emptying, and signals satiety in the hypothalamus. Native GLP-1 lasts only minutes in circulation because the enzyme DPP-4 breaks it down quickly.

How receptor agonists extend the effect

GLP-1 receptor agonists are peptides, and increasingly small molecules, that engage the GLP-1 receptor while resisting DPP-4 degradation, stretching the half-life from minutes to hours or days. They reproduce native GLP-1 effects at a pharmacological level: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite through central satiety signaling. Dual GIP/GLP-1 agonists such as tirzepatide add a second incretin receptor.

Which medications belong to the class

Approved GLP-1 receptor agonists as of April 2026 include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), lixisenatide historically before its U.S. discontinuation, and semaglutide (Ozempic, Wegovy, Rybelsus). The GIP/GLP-1 dual agonist is tirzepatide (Mounjaro, Zepbound). The investigational triple agonist retatrutide has Phase 3 data but is not FDA-approved and is not sold by PlexusDx. Oral non-peptide agonists such as orforglipron are in late-stage development.

Indications across the class

Approved indications differ by product: type 2 diabetes for most, chronic weight management for Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for Ozempic, Trulicity, Victoza, and Rybelsus, and obstructive sleep apnea in adults with obesity for Zepbound as of December 2024. Certain products also carry pediatric indications. Labeling governs what is prescribed for which use.

The safety profile they share

Every approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Contraindications include a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. The most common side effects are gastrointestinal and peak during escalation, while serious reported events include pancreatitis, gallbladder problems, and dehydration-related acute kidney injury.

The genes beneath the pathway

Variants in FTO, MC4R, and TCF7L2 shape baseline GLP-1 activity, appetite regulation, and energy balance. They are pathway-level markers that describe the terrain every compound operates on rather than predicting response to any one drug. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, a non-pharmacogenomic view that complements the Weight Management Protocols.

Why half-life engineering matters

The single most important design problem in this class is time. Native GLP-1 disappears within minutes because DPP-4 dismantles it almost immediately, which makes the natural hormone useless as a medication on its own. Every approved agonist is essentially an answer to that problem, engineered to resist degradation and stretch activity from minutes into hours or days. That is why dosing intervals differ so much across products, from daily to weekly, and why formulation science, including absorption enhancers for oral versions, sits at the center of the field. Understanding this makes the rest of the class easier to read: differences in convenience, dosing rhythm, and delivery route largely trace back to how each product solves the half-life challenge. It also frames why the genetic layer is upstream of all of it, describing the receptor biology these engineered molecules are built to engage.

Zooming out, the class makes sense as a set of engineered answers to one hormone's limitations, each product differing mainly in how it solves durability and delivery. The shared pathway, shared safety story, and shared genetic backdrop are what tie an otherwise varied family of medications together.

Frequently Asked Questions

What is a GLP-1 receptor agonist?

It is a peptide or emerging small molecule that engages the GLP-1 receptor and resists rapid enzymatic breakdown. It stimulates glucose-dependent insulin secretion, slows gastric emptying, and signals satiety. Approved examples include semaglutide, tirzepatide as a dual GIP/GLP-1 agonist, liraglutide, and dulaglutide, each governed by its own FDA label.

How do dual GIP/GLP-1 agonists differ?

Standard agonists engage only the GLP-1 receptor, while dual agonists such as tirzepatide also engage the GIP receptor, adding a second incretin mechanism. Trial data from SURPASS and SURMOUNT suggests the dual-receptor approach may produce larger mean effects on weight and glycemic control in some study populations.

Is retatrutide available now?

No. Retatrutide is an investigational triple agonist with Phase 3 data but no FDA approval as of April 2026, and it is not sold by PlexusDx. Any discussion of it belongs to research literature rather than a treatment option, and dosing figures are intentionally not provided here.

Do genes decide which GLP-1 drug works?

No. The Precision Peptide Genetic Test does not predict response to any compound in the class. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, offering upstream context that applies across every receptor agonist and dual agonist.

Keep learning across the PlexusDx Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.